The long-term results of the Optic Neuritis Treatment Trial (ONTT)1 will certainly allow clinicians to provide clearer information to people presenting with an initial episode of optic neuritis and may also facilitate better design of treatment trials.
Although it is unlikely that many patients in the sample had their serum tested for neuromyelitis optica (NMO) IgG, it would be interesting to know how many went on to develop a longitudinally extensive spinal cord lesion as it is possible that some of them now fulfill the revised diagnostic criteria for NMO as proposed by Wingerchuk et al.2 Furthermore, the data may suggest ways of predicting the future development of NMO, especially as characteristic brain magnetic resonance imaging features have been described.3,4
Gotkine M. Neuromyelitis Optica and the Optic Neuritis Treatment Trial. Arch Neurol. 2008;65(11):1545–1546. doi:10.1001/archneur.65.11.1545-c
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: